Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03428958 2025-04-23

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Phase 1/2 Completed

111 enrolled 22 charts

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT05319639 2025-02-27

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Phase 1/2 Recruiting

51 enrolled

Gastrointestinal

Stomach Neoplasms

NCT01681472 2020-09-25

PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer

Phase 1/2 Completed

32 enrolled 52 charts

Gastrointestinal

Colonic Neoplasms, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01611857 2016-11-23

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

Phase 1/2 Completed

49 enrolled 12 charts

GastrointestinalOther solid neoplasm

Malignant Solid Tumour

Clinical Trials

MK-3475-06C

MK-3475-06E

MK-9999-02A

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach